Hemab Therapeutics Holdings Inc
COAGHealthcare|Biotechnology|USA
$38.09
+0.83 (+2.23%)
Upcoming Data Readouts (4)
Dec 2026
Est. completion
Von Willebrand Disease (VWD)
A Study of Bleeding and Treatment in Participants With Von Willebrand Disease
NCT06610201n=200
Jul 2027
Est. completion
P1P2Von Willebrand Disease (VWD)
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
NCT06754852n=108
Aug 2027
Est. completion
P1P2Glanzmann Thrombasthenia
A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia
NCT06211634n=57
Jun 2035
Est. completion
Hematologic Disorder
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT04398628n=3,000